Xponance, Inc. Intellia Therapeutics, Inc. Transaction History

Xponance, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 13, 2023	BUY	$34.58 - $46.03 $178,536 - $237,652	5,163 New	5,163 $210,000
Q3 2022 Oct 24, 2022	BUY	$53.92 - $71.7 $11,323 - $15,057	210 Added 5.2%	4,250 $238,000
Q2 2022 Aug 02, 2022	BUY	$38.49 - $76.21 $28,174 - $55,785	732 Added 22.13%	4,040 $209,000
Q1 2022 Apr 20, 2022	BUY	$58.27 - $118.99 $815 - $1,665	14 Added 0.43%	3,308 $240,000
Q4 2021 Jan 31, 2022	BUY	$100.76 - $138.36 $4,735 - $6,502	47 Added 1.45%	3,294 $389,000
Q3 2021 Nov 05, 2021	SELL	$132.37 - $176.78 $33,224 - $44,371	-251 Reduced 7.18%	3,247 $436,000
Q2 2021 Aug 12, 2021	BUY	$60.88 - $161.91 $212,958 - $566,361	3,498 New	3,498 $566,000

316

90.6M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $725M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

Stay updated on Xponance, Inc. with notifications on news.